HLA risk markers for chronic myelogenous leukemia in Eastern Canada

Leukemia and Lymphoma

Volumn 50, Issue 2, 2009, Pages 254-259

  Naugler, Christopher ^a   Liwski, Robert ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Chronic myelogenous leukemia; HLA; Risk marker

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA B13 ANTIGEN; HLA B55 ANTIGEN; HLA DR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANADA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAPLOTYPE; HLA TYPING; HOMOZYGOSITY; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPRODUCIBILITY; RISK ASSESSMENT;

ADULT; CANADA; HLA ANTIGENS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 61449252887     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802668873     Document Type: Article

References (37)

1. Sawyers, C. L. (1999) Chronic myeloid leukemia. N Engl J Med, 340, pp. 1330-1340.
2. Pinilla-Ibarz, J., Cathcart, K. and Scheinberg, D. A. (2000) CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev, 14, pp. 111-120.
3. Schmitt, M., Li, L., Giannopoulos, K., Chen, J., Brunner, C. Barth, T. et al. (2006) Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Exp Hematol, 34, pp. 1709-1719.
4. Bocchia, M., Wentworth, P. A., Southwood, S., Sidney, J., McGraw, K. Scheinberg, D. A. et al. (1995) Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood, 85, pp. 2680-2684.
5. Bosch, G. J., Joosten, A. M., Kessler, J. H., Melief, C. J. and Leeksma, O. C. (1996) Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood, 88, pp. 3522-3527.
6. Clark, R. E., Dodi, I. A., Hill, S. C., Lill, J. R., Aubert, G. Macintyre, A. R. et al. (2001) Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood, 98, pp. 2887-2893.
7. Norbury, L. C., Clark, R. E. and Christmas, S. E. (2000) b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol, 109, pp. 616-621.
8. Butt, N. M., Rojas, J. M., Wang, L., Christmas, S. E., Abu-Eisha, H. M. and Clark, R. E. (2005) Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. Haematologica, 90, pp. 1315-1323.
9. Hester, J. P., Rossen, R., Trujillo, J., McCredie, K. B. and Freireich, E. J. (1977) Frequency of HLA antigens in chronic myelocytic leukemia. South Med J, 70, pp. 691-693.
10. Ruuska, P., Silvennoinen-Kassinen, S., Timonen, T. and Tiilikainen, A. (1985) Chronic myelocytic leukaemia: HLA association and decreased erythrocyte C3b receptor expression. Clin Exp Immunol, 59, pp. 300-304.
11. Oguz, F. S., Kalayoglu, S., Diler, A. S., Tozkir, H., Sargin, D. Carin, M. et al. (2003) HLA system affects the age-at-onset in chronic myeloid leukemia. Am J Hematol, 73, pp. 256-262.
12. Posthuma, E. F., Falkenburg, J. H., Apperley, J. F., Gratwohl, A., Roosnek, E. Hertenstein, B. et al. (1999) HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood, 93, pp. 3863-3865.
13. Posthuma, E. F., Falkenburg, J. H., Apperley, J. F., Gratwohl, A., Hertenstein, B. Schipper, R. F. et al. (2000) HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia, 14, pp. 859-862.
14. Rosas-Cabral, A., Irigoyen, L., Alvarado, L., Vela-Ojeda, J., Ayala-Sanchez, M. Tripp-Villanueva, F. et al. (2003) HLA CW3 and HLA CW4 have a protective effect on acquisition of chronic myeloid leukemia on Mexican patients. Rev Invest Clin, 55, pp. 423-428.
15. Amirzargar, A. A., Khosravi, F., Dianat, S. S., Alimoghadam, K., Ghavamzadeh, F. Ansaripour, B. et al. (2007) Association of HLA class II allele and haplotype frequencies with chronic myelogenous leukemia and age-at-onset of the disease. Pathol Oncol Res, 13, pp. 47-51.
16. Khosravi, F., Amirzargar, A., Sarafnejad, A., Nicknam, M. H., Alimoghadam, K. Dianat, S. et al. (2007) HLA class II allele and haplotype frequencies in Iranian patients with leukemia. Iran J Allergy Asthma Immunol, 6, pp. 137-142.
17. Chhaya, S. U. (2006) Human leukocyte antigens in Indian patients with chronic myeloid leukemia. Leuk Lymphoma, 47, pp. 291-295.
18. Li, D., Xi, B., Liu, H. Y. and Yu, Y. (2005) Association of gene HLA-class I with leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 13, pp. 563-566.
19. Miao, K. R., Pan, Q. Q., Xue, M., Fan, S., Wang, X. Y. Pan, M. et al. (2007) Human leukocyte antigens in 295 Chinese patients with chronic myeloid leukemia. Leuk Lymphoma, 48, pp. 2152-2156.
20. Tian, H., Zhou, S. Y., Liu, Z. H., Fu, Y. G., Lu, F. J. Lin, J. H. et al. (2003) Association of HLA-DPB1 alleles with chronic myelogenous leukemia in southern Chinese Hans. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 11, pp. 266-268.
21. Yasukawa, M., Ohminami, H., Kojima, K., Inokuchi, K., Nishimura, Y. and Fujita, S. (2000) Analysis of HLA-DRB1 alleles in Japanese patients with chronic myelogenous leukemia. Am J Hematol, 63, pp. 99-101.
22. Garcia-Lora, A., Algarra, I. and Garrido, E. (2005) MHC class I antigens, immune surveillance, and tumour immune escape. J Cell Physiol, 195, pp. 346-355.
23. Dorak, M. T., Chalmers, E. A., Gaffney, D., Wilson, D. W., Galbraith, I. Henderson, N. et al. (1994) Human major histocompatibility complex contains several leukemia susceptibility genes. Leuk Lymphoma, 12, pp. 211-222.
24. Corsten, P. G., Blight, C. E., Riddell, D. C., Hamilton, D. C. and Cole, D. E. (1994) Molecular diagnosis of cystic fibrosis in Maritime Canada. Clin Invest Med, 17, pp. 1-8.
25. Greene-Davis, S. T., Neumann, P. E., Mann, O. E., Moss, M. A., Schreiber, W. E. Welch, J. P. et al. (1997) Detection of a R173W mutation in the porphobilinogen deaminase gene in the Nova Scotian "foreign Protestant" population with acute intermittent porphyria: A founder effect. Clin Biochem, 30, pp. 607-612.
26. Greer, W. L., Riddell, D. C., Gillan, T. L., Girouard, G. S., Sparrow, S. M. Byers, D. M. et al. (1998) The Nova Scotia (type D) form of Niemann-Pick disease is caused by a G3097->T transversion in NPC1. Am J Hum Genet, 63, pp. 52-54.
27. StatView for Windows version 4.57, Abacus Concepts Inc. 1992-1996, Berkeley, CA
28. Rice, W. R. (1989) Analyzing tables of statistical tests. Evolution, 43, pp. 223-225.
29. Review Manager (RevMan) [computer program] (2003) Version 4.2 for windows, the Nordic Cochrane Centre, the Cochrane Collaboration, Copenhagen
30. CPRA calculator [Internet] United Network for Organ Sharing
31. High Resolution HLA Alleles and Haplotypes in the US Population [Internet] National marrow donor program
32. Ebeling, S. B., Ivanov, R., Hol, S., Aarts, T. I., Hagenbeek, A. Verdonck, L. F. et al. (2003) HLA-DRB1*16-restricted recognition of myeloid cells, including CD34+ CML progenitor cells. Br J Haematol, 121, pp. 721-729.
33. Pawelec, G. and Wagner, W. (2001) Is HLA-DR4 or the HLA-DRB1*0402 allele associated with decreased risk for CML?. Leukemia, 15, pp. 192-193.
34. Yasukawa, M., Ohminami, H., Kojima, K., Hato, T., Hasegawa, A. Takahashi, T. et al. (2001) HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+)T lymphocytes. Blood, 98, pp. 1498-1505.
35. Yasukawa, M., Ohminami, H., Kaneko, S., Yakushijin, Y., Nishimura, Y. Inokuchi, K. et al. (1998) CD4+cytotoxic T cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenenous leukemia cells in a b3a2-specific and HLA-DR-4 restricted manner. Blood, 92, pp. 3355-3361.
36. Sun, J. Y., Senitzer, D., Forman, S. J., Chatterjee, S. and Wong Jr., K. K. (2003) Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes. Cancer Immunol Immunother, 52, pp. 761-770.
37. MacIntyre, A. R., Christmas, S. E. and Clarke, R. E. (1996) The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide. Exp Hematol, 24, pp. 1307-1311.